Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.